licensed access to BioWa
® Technology for the research, development, and commercialization of its antibody therapies. Under this nonexclusive agreement, BioWa received up-front fees and may earn development milestone payments and royalties.
Potelligent is designed to improve potency and efficacy of antibody therapeutics by enhancing antibody-dependent cellular cytotoxicity. It involves the reduction of the amount of fucose in the carbohydrate structure of an antibody using a proprietary fucosyltransferase-knockout CHO cell line as a production cell.